<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6420">
  <stage>Registered</stage>
  <submitdate>6/04/2017</submitdate>
  <approvaldate>6/04/2017</approvaldate>
  <nctid>NCT03109730</nctid>
  <trial_identification>
    <studytitle>Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B</studytitle>
    <scientifictitle>A Phase 1b/2a, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Patients With Chronic Hepatitis B</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ABI-H0731-101B</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Hepatitis b</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABI-H0731
Treatment: drugs - Placebo for ABI-H0731
Treatment: drugs - Entecavir
Treatment: drugs - Tenofovir Disoproxil Fumarate
Treatment: drugs - Pegasys

Experimental: Cohort B1 - ABI-H0731 or Placebo in varying doses by mouth for 28 days

Experimental: Cohort B2 - ABI-H0731 or Placebo in varying doses by mouth for 28 days

Experimental: Cohort B3 - ABI-H0731 or Placebo in varying doses by mouth for 28 days

Experimental: Cohort B4 - ABI-H0731 or Placebo in varying doses by mouth for 28 days

Experimental: Cohort B5 - ABI-H0731 or Placebo in combination with entecavir or tenofovir for 28 days

Experimental: Cohort B6 - ABI-H0731 or Placebo, in combination with a commerically-approved nucleos(t)ide plus PegIFN in treatment-experienced patients, for 28 days


Treatment: drugs: ABI-H0731
A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients

Treatment: drugs: Placebo for ABI-H0731
Sugar pill manufactured to mimic the ABI-H0731 tablet

Treatment: drugs: Entecavir
An antiviral medication used in the treatment of hepatitis B virus infection

Treatment: drugs: Tenofovir Disoproxil Fumarate
An antiviral medication used in the treatment of hepatitis B virus infection

Treatment: drugs: Pegasys
Used to treat adults with chronic hepatitis B virus who show signs of liver damage

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of patients with chronic HBV infection with treatment-related adverse events and laboratory abnormalities as assessed by CTCAE v4.0.</outcome>
      <timepoint>Up to 57 days</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female, 18 to 65 years of age

          -  Chronic HBV infection

          -  Body Mass Index (BMI) 18-38 kg/m2 and a minimum body weight of 45 kg</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Seropositive for HIV, HCV, or HDV antibody at Screen

          -  Previous treatment with any investigational HBV antiviral treatments within the last 6
             months

          -  Other known cause of liver disease, including NASH

          -  Other medical condition that requires persistent medical management or chronic or
             recurrent pharmacologic or surgical intervention</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Other</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>15/06/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC,WA</recruitmentstate>
    <hospital>Monash University - Clayton</hospital>
    <hospital>St. Vincent's Hospital - Fitzroy</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <hospital>Linear Clinical Research - Nedlands</hospital>
    <postcode> - Clayton</postcode>
    <postcode> - Fitzroy</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Chuncheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Keelung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Assembly Biosciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this protocol is to obtain pharmacodynamic and pharmacokinetic data on
      ABI-H0731 and to provide the opportunity for preliminary evaluation of combination therapy of
      ABI-H0731 with currently approved antiviral treatment for chronic hepatitis B.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03109730</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Assembly Biosciences Clinical Trials</name>
      <address />
      <phone>1-855-971-4467</phone>
      <fax />
      <email>clinicaltrials@assemblybio.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>